In situ expression of a foreign antigen and an immune-modulating cytokine by intratumoral DNA electroporation was tested as a cancer therapy regimen. Transgene expression in the tumors was sustained for 2-3 weeks after intratumoral electroporation with mammalian expression plasmid containing WreXy luciferase cDNA. Electroporation with cDNA encoding tetanus toxin fragment C (TetC) induced tetanus toxin-binding antibody, demonstrating immune recognition of the transgene product. Intratumoral electroporation with TetC and IL-12 cDNA after mice were treated with CD25 mAb to remove regulatory T cells induced IFN-producing T-cell response to tumorassociated antigen, heavy inXammatory inWltration, regression of established tumors and immune memory to protect mice from repeated tumor challenge. Intratumoral expression of immune-modulating molecules may be most suitable in the neoadjuvant setting to enhance the therapeutic eYcacy and provide long-term protection.
Introduction
The response to neoadjuvant or pre-operative chemotherapy has been correlated with overall survival, showing the importance of minimizing tumor load before deWnitive surgery [1, 9, 21] . It would be most advantageous to amplify anti-tumor immunity during neoadjuvant therapy to enhance long-term disease-free survival.
Tumor tissue is a rich reservoir of tumor-associated antigens (TAA), but endogenous immunity to TAA fails to reject tumors in cancer patients [14, 22, 26] . To amplify anti-tumor immunity, immunostimulatory molecules may be introduced systemically, but drug toxicity and induction of autoimmunity are dose limiting. There have been prior attempts to directly modulate tumors to avoid systemic side eVects. Glycolipid containing -gal (Galalpha1-3Galbeta1-4GlcNAc-R) was inserted into tumor cell membrane for recognition by the abundant natural anti--gal Ab in humans [6] . CCL20 chemokine has been delivered to the tumor to recruit inXammatory cells [5] , and MHC class II transactivator was expressed in the tumor to enhance antigen presentation to CD4 T cells [18] . Other immune-modulating molecules, such as CpG-ODN [29] , LIGHT [36] , IL-12 [19] , CD40L [17] , or GM-CSF [4] have been introduced in the form of nucleotides, proteins, plasmid DNA, or viral vectors. Some anti-tumor activity was achieved with these regimens, but the results have been variable.
We previously showed that removal of CD4
Treg by CD25 mAb resulted in the regression of established TUBO tumors that expressed rat neu and the induction of sustained anti-neu immunity in wt BALB/c, but not in neu-tolerant BALB NeuT transgenic mice [12, 33] . Therefore, the foreign neu expressed by the tumor cells facilitated tumor rejection in the Treg-depleted environment.
Tetanus toxin fragment C (TetC), a non-toxic, immunogenic fragment of tetanus exotoxin [10] that contains a universal CD4 T-cell epitope [23] , is a candidate molecule to facilitate immune priming in the tumor. In the US population, tetanus toxin is a recall antigen due to prophylactic immunization and may be exploited in cancer immunotherapy [15, 30] . TetC DNA has functioned as an adjuvant in speciWc cancer vaccines [3, 30] . Here, we tested the hypothesis that intratumoral expression of TetC in Treg-depleted mice would induce immune priming to endogenous tumor-associated antigens. Plasmid DNA was used to deliver exogenous genes because it is free of confounding foreign entities and can be administered repeatedly, allowing continuous expression of the encoded molecules. Although only a fraction of the tumor cells was transfected in vivo, expression of secreted TetC (SecTetC) induced immune priming to tumor-associated antigens. When combined with IL-12, the treatment resulted in tumor regression or growth retardation and protective immune memory.
Materials and methods

Mice
All animal procedures were conducted in accordance with accredited institution guidelines and the US Public Health Service Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/olaw.htm#pol). C57BL/6 and BALB/c (age 6-12 weeks) mice were purchased from Charles River Laboratory (Frederick, MD) or bred in our animal facility.
Cell lines and reagents
Cell lines were cultured as previously described [11, 13] . BALB/c mouse mammary tumor lines D2F2 [20] , D2F2/E2 [34] , TUBO [2, 28] , and C57BL/6 TC-1 lung cell line [16] have been described previously. TUBO and TC-1 were provided by Dr. Guido Forni, University of Turin, Orbassano, Italy and Dr. T.C. Wu, the Johns Hopkins University, Baltimore, MD, respectively. D2F2 cells were co-transfected with pGL3 (Promega, Madison, WI) and pRSV2/neo to generate D2F2/Luc cells that stably express luciferase. C57BL/6 mammary tumor line E0771 was obtained from the late Dr. Gordon Ross (University of Louisville, Louisville, KY).
Plasmid DNA and in vivo DNA electroporation pGL3 encoding WreXy luciferase under CMV promoter was purchased from Promega. pNGVL3-mIL-12 encoding murine IL-12 subunits p35 and p40 separated by IRES was purchased from National Gene Vector Lab (Ann Arbor, MI). pSecTag2B was from Invitrogen. pEFBos/GM-CSF (pGM-CSF) encoding murine GM-CSF was provided by Dr. N. Nishisaka (Osaka University, Osaka, Japan).
pLPCX/TetC containing human codon-optimized cDNA of TetC was obtained from Dr. Suzanne Ostrand-Rosenberg (University of Maryland, Baltimore, MD). A 1.37-kb Hin-DIII/BamHI fragment encoding full length TetC, aa 1-452, was isolated from pLPCX/TetC and ligated into pSecTag2B. The Ig leader sequence is in frame with the 5Ј end of TetC. The orientation and integrity of the inserted sequences were veriWed by restriction analysis and DNA sequencing.
For intratumoral DNA electroporation, mice were inoculated subcutaneously (s.c.) with 1-2 £ 10 5 indicated tumor cells. When tumors reached 2 £ 2 to 3 £ 3 mm, mice were anesthetized with ketamine/xylazine, and 100 g of each indicated plasmid DNA was injected into the tumor in a total volume of 50 l of sterile saline using a tuberculin syringe with a 26-gauge needle. Needle was inserted into the tumor mass, and DNA solution was slowly dispensed into the tumor along the needle track, while the needle was being withdrawn. The injection was followed immediately by square wave electroporation using BTX830 apparatus (BTX Harvard Apparatus, Holliston, MA). Tweezers applicator was placed around the tumor to deliver eight pulses at 100 V for 20 ms. Intratumoral treatment was repeated after 3-6 days. Tumor growth was monitored by weekly palpation and tumor volume was calculated by X 2 Y/2, where X and Y represent the short and long dimensions, respectively. Comparison of tumor volume at a given time point was analyzed by one-tail Student's t test. DiVerences in tumor incidence were analyzed by log-rank test.
Western blot analysis of recombinant SecTetC protein Serum-free culture supernatants were collected from BALB/c NIH 3T3 Wbroblasts transfected with SecTetC DNA, concentrated 13-fold using Millipore Centricon YM-10 (Millipore, Bedford, MA) and analyzed by Western blot as described previously [24] . Membranes were hybridized with goat anti-tetanus exotoxin IgG (Cortex Biochem, Concord, MA) or sera from mice immunized with pSecTetC, followed by labeling with HRP-conjugated donkey antigoat or goat anti-mouse Ab (Santa Cruz Biotechnology, Santa Cruz, CA). The membranes were developed with enhanced SuperSignal® West Pico Chemiluminescent Substrate (Pierce Biotechnology, Inc., Rockford, IL) and imaged with IS4000 imager (Kodak, New Haven, CT). Recombinant TetC was the positive control.
Measurement of anti-TetC Ab by ELISA
The 96-well Xat bottom microtiter ELISA plates were precoated by overnight incubation with 50 l of 0.25 Xocculation units/ml adsorbed tetanus toxoid (SanoW Aventis, Bridgewater, NJ). The plates were incubated with immune sera and bound IgG was detected with goat anti-mouse-HRP (Santa Cruz Biotechnology) and ABTS substrate. DiVerences in Ab concentration were analyzed by Student's t test.
Treg depletion
To deplete CD25
hi Treg, mice were injected i.p. with 60 g PC61 (ATCC, Manassas, VA) mAb, 1 day after tumor implantation. Depletion of CD25 hi T cells was veriWed by Xow cytometry, as previously described [27, 33] .
In vivo and ex vivo luciferase assays At indicated times following intratumoral pGL3 electroporation, mice were anesthetized with ketamine/xylazine and injected i.v. with 1.6 mg D-luciferin (BD Biosciences, San Jose, CA). Luminescence and X-ray images were obtained with an IS4000MM multimodal imager (Kodak) and the levels of bioluminescence were analyzed using MetaMorph software (Molecular Devices). As positive control, D2F2/Luc tumor cells stably transfected with luciferase were injected s.c. into the opposite Xank. As an additional control, 50 g of pGL3 in 25 l PBS was injected into the quadriceps of mice, followed by electroporation [11, 13] .
For ex vivo activity assay, tumors were electroporated twice, 3 days apart with saline or pGL3 before they were removed 7 or 10 days after initiation of DNA electroporation. The tumor tissue was weighed and dissociated into single cell suspension, prior to lysis with 1£ CCLR buVer (Promega). Luciferase activity was measured using a Promega in vitro luciferase assay system, and protein concentration was calculated using QuantiLum recombinant luciferase as the standard.
Measurement of T-cell response by ELISpot assay
All ELISpot reagents were purchased from BD Biosciences. Her-2-reactive T cells in tumor-draining lymph nodes were enumerated by IFN-and IL-5 ELISpot assay, as previously described [13, 27] . Data were analyzed using the one-tail Student's t test.
Immunohistochemistry
Tissue sections of the tumors and draining lymph nodes were stained with hematoxylin and eosin, and histological images were collected with a Zeiss microscope using a Sony 970 CCD camera interfaced with the MCID7 imaging software package.
Results
Kinetics of protein expression after intratumoral DNA electroporation
To evaluate the level and duration of gene expression by intratumoral DNA electroporation, BALB/c mice were inoculated s.c. in the right Xank, with D2F2 mammary tumor cells. When the tumors were 2 £ 2 mm or greater, pGL3 DNA encoding WreXy luciferase was injected into the tumor, followed immediately by electroporation over the injection site. The procedure was repeated in 3 days. To measure luciferase activity, the enzyme substrate D-luciferin was injected i.v. 1-week after DNA electroporation. Luminescence (Fig. 1a, left panel) , and X-ray (Fig. 1a , middle panel) images were acquired and superimposed (Fig. 1a, right panel) to illustrate the concordance between the light emitted from cleavage of D-luciferin and the location of tumor (Fig. 1a, "1") , thus demonstrating luciferase activity in the treated tumor. Each mouse also received pGL3 electroporation into the right quadriceps muscle with corresponding luminescence (Fig. 1a, "2") . Therefore, luciferase was expressed whether luciferase cDNA was electroporated into the tumor or muscle. As a positive control, D2F2/Luc cells stably transfected with luciferase were injected into the opposite Xank, and luminescence of the tumor was evident (Fig. 1a, "3") .
To measure the kinetics of recombinant luciferase expression, Wve BALB/c mice were inoculated s.c. with D2F2 tumors, followed by two-time intratumoral pGL3 electroporation. Relative luminescence intensity was recorded at 6 h and on days 2, 4, 7, 10, 14, 17, 21, 24, 30, and 37 after the initial DNA electroporation (Fig. 1b) . Luminescence was detected in all Wve test mice at 6 h. With some Xuctuation, luminescence at 100-250 £ 10 3 relative luminescence units was sustained for 2-3 weeks before declining. Luciferase activity was also detected after intramuscular DNA electroporation for 3-4 weeks (data not shown). Therefore, DNA electroporation resulted in localized gene expression at the site of injection.
Luciferase gene expression was veriWed ex vivo in a repeated experiment. On days 7 and 10 after intratumoral pGL3 electroporation, tumors were removed and dissociated. Luciferase activity in tumor lysates was measured as described in "Materials and methods", and enzyme concentration calculated using QuantiLum recombinant luciferase as the standard. Luciferase activity was detected in all four treated tumors (Fig. 1c, Wlled circles) , but not in the Wve control tumors (Fig. 1c, open circles) .
To test if DNA electroporation was applicable to other solid tumors, pGL3 expression was tested in BALB/c mice bearing TUBO tumor and C57BL/6 mice bearing E0771 or TC-1 tumor. Luminescence was detected when measured on days 7 or 10 after intratumoral pGL3 electroporation (Fig. 1d) . Therefore, consistent gene expression was achieved in all test tumors, showing the feasibility of using intratumoral DNA electroporation as a standard treatment regimen.
Construction and characterization of pSecTetC encoding a secreted tetanus toxin fragment C (TetC)
TetC contains a promiscuous helper epitope, p30, which can be presented by several mouse and human MHC class II alleles, and Ab to TetC recognize tetanus toxin [10] . Because the bacterial coding sequence does not translate eYciently in mammalian cells, TetC sequence optimized for mammalian expression [31] was used to construct pSecTetC that encodes a secreted protein for antigen dispersion in the tumor after in vivo transfection (Fig. 2a) . NIH 3T3 Wbroblasts were transiently transfected with pSecTetC, and a »64 kDa band was detected in the culture supernatant by Western blotting using goat anti-tetanus exotoxin Ab (Fig. 2b) , showing secretion of SecTetC by transfected cells. The 50 kDa recombinant bacterial TetC (rTetC) was the positive control. The higher molecular weight of SecTetC produced by transfected cells was likely the result of protein glycosylation in mammalian cells.
To test the immunogenicity of SecTetC, BALB/c mice were electrovaccinated once, i.m. with pSecTetC and pGM-CSF. Anti-TetC Ab was detected by Western blotting against SecTetC from the culture supernatant (Fig. 2c) . Binding to the 64 kDa, SecTetC was detected with immune, but not control, mouse sera, showing the induction of anti-TetC Ab by pSecTetC electrovaccination.
To test whether immune sera also recognized the native bacterial tetanus protein, binding of immune sera to tetanus toxoid was measured by ELISA (Fig. 2d) . pSecTetC immune sera, but not control sera, bound to tetanus toxoid. Therefore, Ab induced by pSecTetC recognized both SecTetC and native bacterial tetanus toxoid, demonstrating the immunogenicity of pSecTetC.
Immune responses to TetC were induced by intratumoral DNA electroporation
To enhance immune response, mice were treated with 60 g CD25 mAb 1 day after tumor injection, which was previously shown to deplete CD25 hi
Foxp3
+ cells for about 3 weeks [27] . In mice inoculated with D2F2 tumor, 60 g CD25 mAb and intratumoral electroporation of blank vector reduced tumor growth in one of seven mice (Supplementary Fig. S1 ), showing minimal impact of Treg depletion and blank vector treatment.
To test if pSecTetC administered into the tumor induces immune response, BALB/c mice inoculated with D2F2 tumor were electroporated with pSecTetC in the tumor when the tumors were 2-3 mm in diameter (Fig. 3, left  panel) . Humoral immune response to TetC was detected in the immune sera 2 weeks later at 1:200 dilution by the Mouse control immune sera Control pSecTetC binding to tetanus toxoid using ELISA (Fig. 3, right panel) . Treatment with CD25 mAb further enhanced the antibody response (Fig. 3, right panel) . Therefore, SecTetC was expressed by intratumoral DNA electroporation to mount a signiWcant immune response.
Inhibition of D2F2 tumor growth by expressing SecTetC and IL-12 in the tumor
To test the anti-tumor eYcacy, BALB/c mice inoculated with D2F2 tumor received CD25 mAb and two-time intratumoral electroporation with pSecTetC and pIL-12. All mice treated with blank vector showed progressive tumor growth (Fig. 4a) . In mice treated with pSecTetC, one tumor (25%) regressed after week 3. In mice receiving pIL-12, two of Wve (40%) tumors regressed after week 3. When mice received both pSecTetC and pIL-12, Wve of eight (63%) tumors regressed after transient growth (Fig. 4a) . Therefore, signiWcant tumor rejection was achieved by lowdose CD25 mAb and intratumoral electroporation with pSecTetC and pIL-12. This experiment has been repeated twice with similar results, i.e., pSecTetC + pIL-12, > pIL-12 > pSecTetC in tumor growth inhibition. But, statistically signiWcant diVerence was not always observed between the pSecTetC + pIL-12 and pIL-12 group. Treg depletion was critical in this regimen, because tumorbearing mice, which received pSecTetC and pIL-12 without prior treatment with CD25 mAb showed only modest reduction in tumor growth (not shown), demonstrating the importance of reducing negative regulation in this therapy regimen.
Histological analysis of control D2F2 tumors (Fig. 4b,  left panel) showed a poorly diVerentiated carcinoma that consisted of solid nests of polygonal to spindle-shaped tumor cells undergoing frequent central necrosis and separated by a delicate stromal network. Tumor cells had sharply deWned borders, a moderate amount of eosinophilic cytoplasm, a high nuclear to cytoplasm ratio, and hyperchromatic and pleomorphic round to elongated nuclei with frequent nucleoli and abundant mitotic Wgures. Tumors treated with intratumoral pSecTetC and pIL-12 DNA electroporation (Fig. 4b, right panel) , however, showed massive lymphocytic inWltration surrounding a core of necrotic debris, indicating immune-mediated destruction of treated tumors.
Immune memory induced by tumor regression following DNA electroporation
In a repeated experiment to test if immune memory was induced, BALB/c mice were inoculated with D2F2 tumor, treated with CD25 mAb and electroporated with pSecTetC and pIL-12. The tumors in the four control mice that received CD25 mAb and blank vector grew progressively (Fig. 5a, top panel) . In contrast, Wve of nine (56%) tumors that received pSecTetC and pIL-12 regressed completely by week 6 (Fig. 5a , bottom panel). Mice that rejected D2F2 tumors were rechallenged at week 12 in the opposite Xank with the same tumor (Fig. 5b) , and all were protected from a second D2F2 challenge, while progressive tumors developed in control mice. Taken together, these data showed that electroporation of pSecTetC and pIL-12 in the tumor following Treg depletion resulted in anti-tumor immunity and long-term memory.
Immune response to TAA induced by intratumoral DNA electroporation
To test immune priming to a speciWc TAA by intratumoral DNA electroporation, BALB/c mice were inoculated with Her-2-positive D2F2/E2 tumor cells, treated with 60 g of CD25 mAb and intratumoral electroporation with pSecTetC, pIL-12, or both. Tumor-draining lymph nodes were removed 2 weeks after DNA treatment and lymph node cells were pooled from two to three mice in each group. Her-2-speciWc T-cell response was measured by ELISpot assay. Anti-Her-2 IFN--producing T cells were detected in immune lymph nodes by incubation with engineered antigen presenting cells 3T3/EKB, which expressed Her-2, K d and CD80 (B7.1). Her-2-speciWc IFN-T cells were induced by pSecTetC (212 § 19/10 6 lymph node cells), pIL-12 (147 § 72/10 6 ), and pSecTetC + pIL-12 (370 § 89/ 10 6 ), with pSecTetC + pIL-12 showing the highest activity (p < 0.01 compared to mice receiving single treatment) (Fig. 6) . IL-5 producing T cells were not detected (data not shown), showing preferential induction of Th1 response. Therefore, a strong Th1/Tc1 response to tumor-associated Her-2 was induced. Induction of anti-tumor immunity by in situ immune priming via intratumoral expression of a foreign antigen and IL-12 may be very beneWcial in the neoadjuvant setting.
Discussion
In the current study, reduction of tumor growth and in situ priming to TAA indicate that intratumoral DNA electroporation after Treg depletion may be a plausible neoadjuvant regimen. Profound inhibition of primary tumor growth was observed. Importantly, immune response to TAA was induced to protect against tumor rechallenge, supporting the potential eYcacy of intratumoral gene therapy in * neoadjuvant setting. In a neoadjuvant trial, patients with locally advanced breast cancer who achieved complete clinical response to preoperative chemotherapy had a 75% 9-year overall survival, compared to 65% in non-responders [35] . In a bladder cancer trial, the median survival was 77 months versus 46 months in patients receiving neoadjuvant chemotherapy compared to surgery alone [8] . In such neoadjuvant setting, induction of immune memory by intratumoral DNA electroporation may enhance long-term protection. TetC has been described as a vaccine adjuvant by Buchan et al. [3] , who generated DNA vaccines encoding fusion protein of TetC and tumor antigen AH1 or idiotypic Ab for intramuscular electroporation. TetC enhanced immune response against these designated antigens, resulting in reduced tumor growth. However, when administered intramuscularly without antigen, TetC DNA did not induce anti-tumor immune response. We showed the induction of signiWcant T-cell response to tumor-associated Her-2, when pSecTetC was injected into the tumors where it functions as an in situ adjuvant with the potential to amplify the immune response to all tumor-associated antigens. Anti-tumor eYcacy of pSecTetC may be further ampliWed in preimmunized hosts, such as tetanus-vaccinated individuals in the USA. It is possible that intratumoral electroporation with other immune-modulating cytokines or increased doses of IL-12 may result in tumor rejection. But, the potential to exploit a recall antigen in humans combined with greater eYcacy observed with pSecTetC + pIL-12 shows the beneWt of combined treatment.
Both innate and adaptive immunity may contribute to the observed tumor growth inhibition. IL-12 is a potent NK activator and directs Th1 cell diVerentiation [32] . It is also associated with the inhibition of angiogenesis [32] . Intratumoral delivery of IL-12 by DNA electroporation can reduce tumor growth via immunological and anti-angiogenic mechanisms [19] . TetC is a strong bacterial antigen as demonstrated by the induction of TetC Ab after one-time DNA electroporation. Continuous liberation of both SecTetC and IL-12 results in the strongest immune priming to TAA, such that treated tumors regress or are reduced in size, and demonstrate heavy inXammatory inWltration. The microenvironment modiWed by expressing SecTetC, IL-12, or both favors Th1/Tc1 activation because IFN-, but not IL-5 Tcell response, was induced.
Luciferase expression lasted about 3 weeks after the gene was electroporated into the tumor or muscle, demonstrating the feasibility of sustained in vivo transgene expression. Luciferase expression was detected only after electric pulses were applied (not shown). This localized transgene expression further increases the safety of this treatment. Because plasmid vectors are free of pathogenicity and immunogenicity, the treatment can be repeated as needed with the same or alternative immune-modulating molecules to amplify immune responses [7, 25] .
We have previously shown that mice undergoing tumor regression following Treg depletion had an enhanced immune reactivity to self-antigens, such as thyroglobulin [12, 33] . The approach of intratumoral gene expression focuses the immune response to antigens in the tumor, thus minimizing the need for systemic immune modulation and reducing the risk of autoimmunity.
In conclusion, a new immunotherapy regimen that combines Treg depletion and intratumoral delivery of pSecTetC and pIL-12 has demonstrated potential utility in cancer therapy by inhibiting tumor growth and by in situ immune priming to endogenous TAA. 
